TCI LVAD Trials Hope To Show Device As "Destination Technique"
This article was originally published in The Gray Sheet
Long-term use of electric left ventricular assist devices (LVADs) as a "destination technique" rather than a bridge to transplantation is being examined by Thermo Cardiosystems, Inc.' s REMATCH trial, Eric Rose, MD, Columbia Presbyterian Hospital, told attendees of the American Heart Association's 71st Scientific Sessions Nov. 11 in Dallas.
You may also be interested in...
Baxter Healthcare will continue to distribute products produced by its Cardiovascular Group spin-off in several countries outside of the U.S., including Argentina, Australia, Greece, Ireland, New Zealand and certain Scandinavian countries, after CVG Controlled, Inc. becomes a separate entity in the first half of 2000.
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.